BioCentury | Apr 1, 2020
Distillery Therapeutics

Two glycopeptides for drug-resistant Gram-positive infections

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus; Gram-positive bacterial infections The glycopeptides corbomycin and complestatin could treat methicillin- and daptomycin-resistant S. aureus and other Gram-positive infections by interfering with cell wall remodeling. Complestatin and related compounds...
BC Innovations | Oct 31, 2019
Distillery Therapeutics

Human symbiont-derived antimicrobial peptide for Gram-positive infections

DISEASE CATEGORY: Infectious disease INDICATION: Clostridium ; Gram-positive bacterial infection An antimicrobial peptide produced by the human gut microbiome species Ruminococcus gnavus could treat infections caused by Clostridium and other Gram-positive bacteria. In bacterial culture,...
BC Extra | Oct 4, 2019
Clinical News

Summit’s C. diff benefits for ridinilazole continue with early, sustained effect on quality of life

Summit now has quality-of-life data for its ridinilazole to treat Clostridium difficile infections showing benefits over SOC that could help HTAs such as NICE as they develop new value assessment frameworks to capture the benefits...
BC Innovations | Sep 19, 2019
Targets & Mechanisms

Regeneron's new take on bispecifics: activating complement

Regeneron's new bispecific antibodies for the first time tap the complement system -- going beyond the immune cells traditionally targeted, and expanding the modality into new patient populations and indications. With proof of concept studies...
BC Extra | Aug 29, 2019
Clinical News

Aug. 29 Clinical Quick Takes: Immunicum's off-the-shelf cell therapy misses in Phase II for kidney cancer; plus Acurx and Esperion

Immunicum's cell therapy misses survival endpoint in Phase II RCC trial  Immunicum AB (SSE:IMMU) lost SEK1.46 (14%) to SEK8.86 after reporting that ilixadencel plus Sutent sunitinib from Pfizer Inc. (NYSE:PFE) did not improve 18-month survival,...
BC Innovations | Aug 14, 2019
Distillery Therapeutics

Antihelminthic compound bithionol could treat MRSA infection

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus The antihelminthic bithionol could be repurposed to treat methicillin-resistant S. aureus (MRSA) infections. In bacterial growth assays, bithionol reduced growth of three MRSA strains and a vancomycin-resistant S. aureus...
BC Week In Review | Apr 26, 2019
Company News

Lilly divests China rights to legacy antibiotics to Eddingpharm

Lilly sold Chinese rights to Vancocin vancomycin and Ceclor cefaclor, as well as a Ceclor manufacturing plant in Suzhou, to Eddingpharm for $375 million in a deal slated to close late 2019 or early 2020....
BC Innovations | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BC Innovations | Feb 20, 2019
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient samples and mouse studies suggest an antibiotic cocktail or inhibiting IL22RA1 or IL-17A could help treat lung cancer. In tissue samples from patients with lung adenocarcinoma, levels of IL22RA1 were higher...
BC Week In Review | Oct 12, 2018
Clinical News

Vedanta's CDI product VE303 well tolerated in Phase I

Vedanta Biosciences Inc. (Cambridge, Mass.) said single and multiple ascending doses of VE303 given following vancomycin were well tolerated in 23 healthy adult volunteers in an open-label Phase Ia/Ib trial. The company plans to start...
Items per page:
1 - 10 of 645